Key facts
- Floré’s last known valuation is $35.0M (Dec 2023).
- It has raised $27.1M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Plug and Play Tech Center, SOSV, IndieBio, CONNECT(San Diego), K3 Ventures — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Floré
- ·The full record, as it builds
Funding rounds
No funding rounds for Floré are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Floré
Producer of custom probiotics intended for improving gut health. The company combines microbiome testing and different prebiotics, probiotics, and botanical ingredients to create a custom formulation, reduce constipation, relieve digestive issues, promote food tolerance, support GI motility, support digestive quality of life and support immunity, enabling individuals to address issues such as abdominal pain, constipation, bloating, small intestinal bacterial overgrowth, leaky gut, and other digestive issues.
- Sector
- Consumer Products and Services (B2C)
- HQ
- San Diego, CA, United States
- Founded
- 2016
- Employees
- 11
- Website
- flore.com/
- Ownership
- Privately Held (backing)
Floré doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Floré shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Floré in its N-PORT filings yet. We sweep new filings monthly.